Cleveland Clinic Launches First-of-its-Kind Brain Study Aimed at Diagnosing, Preventing Neurological Diseases Before Symptoms Occur
The landmark study to follow up to 200,000 healthy participants over 20 years
Thursday, January 20, 2022, CLEVELAND: A leading global healthcare system, Cleveland Clinic, has launched a landmark study to better understand why millions of people around the world suffer from brain diseases, with the goal of pinpointing disease biomarkers early, well before clinical symptoms present themselves.
The new Cleveland Clinic Brain Study – the largest clinical study ever for brain disease – will collect data from up to 200,000 neurologically healthy individuals over a 20-year period to identify brain disease biomarkers and targets for preventing and curing neurological disorders.
One in every six people around the globe has a neurological disease such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, stroke or epilepsy. While the medical community has learned to manage some symptoms of brain disorders, it remains challenging to predict who will become sick or how to cure – or even stop the progression of – these diseases once they are diagnosed.
Led by Andre Machado, M.D., Ph.D., and Imad Najm, M.D., of Cleveland Clinic’s Neurological Institute, the longitudinal multi-year study is an enterprise-wide undertaking, enlisting a multidisciplinary team of physicians and scientists from across the global health system. The study launched at Cleveland Clinic’s main campus in Cleveland and will expand to additional Cleveland Clinic sites over time.
“Disrupting neurological diseases is one of the greatest challenges of our time and motivates our clinicians and scientists every day,” said Dr. Machado, chair of the Neurological Institute and the Charles and Christine Carroll Family Endowed Chair in Functional Neurosurgery. “By launching a study of this magnitude, we have the potential to discover causes of neurological disorders and what happens before symptoms become obvious – the silent phase. Our hope is to change the course of neurodegeneration, with the long-term goal of curing diseases in their earliest stages, years before symptoms are even seen. Achieving this will be a great gift to our children and grandchildren. We can make neurological care better for the next generations.”
The initial phase of the study will enroll 10,000 volunteers over the first five years who will be examined and thoroughly investigated. This will include adults 50 years and older with no known neurological disorder or neurologically healthy adults age 20 and older who have a first-degree relative diagnosed with multiple sclerosis. Volunteers do not have to be current Cleveland Clinic patients. Participants will undergo yearly assessments including neurological examination, bloodwork, eye retina scans, brain MRIs, EEG and sleep studies and other cognitive function tests.
Using advanced computing tools, researchers will collect data points from the study volunteers. Collectively, these data points will form a trend line to capture the genetic risk factors, and invisible molecular, structural, neurophysiological and cognitive/memory changes in the brain over time. Researchers will seek “disease fingerprints” to help guide diagnostic and preventative medicines.
“By researching at-risk healthy individuals over the course of 20 years, we will learn what is happening to the brain and body before a neurological disease is diagnosed. This research will help understand the mechanisms of brain diseases and lead to the design of preventive treatment for neurological diseases. This is precision medicine in its best form,” said Dr. Najm, vice chair of the Neurological Institute for Strategy and Development and director of Cleveland Clinic’s Charles Shor Epilepsy Center and the Joseph H. and Ellen B. Thomas Endowed Chair in Epilepsy. “We’re building a foundation to screen one person at a time – potentially with something as routine as a blood test – to diagnose brain disease on the spot and prevent it from happening altogether.”
Philanthropic contributions are funding the study in part, with gifts of all sizes pooled to support the research. Philanthropy is vital in the mix of funding that is launching the research and moving it forward.
For more information about the Cleveland Clinic Brain Study visit: https://my.clevelandclinic.org/departments/neurological/research-innovations/brain-study